Top

Published in:

01-10-2007 | Abstracts

Poster Presentations

Authors: A. S. Lemaire-Hurtel, L. Masson, L. Harry, H. Masson, M. Andrejak

Published in: Drug Safety | Issue 10/2007

Excerpt

Tipranavir is a second-generation dihydropyrone against HIV. This sulphonamide derivative is a nonpeptidic protease inhibitor (NPPI) with a resistance profile distinct from other currently available protease inhibitors (PIs). Concomitant administration of a low-dose of ritonavir (RTV) significantly increases tipranavir (TPV) plasma concentrations. The approved dose of tipranavir is 500 mg with ritonavir 200 mg, twice daily.^[1] …

Drugs RD 2006; 7(1): 55–62

Leibenguth P, et al. Their Drug Monitor 2001, 23(6): 679–88CrossRef

Title: Poster Presentations
Authors: A. S. Lemaire-Hurtel
L. Masson
L. Harry
H. Masson
M. Andrejak
Publication date: 01-10-2007
Publisher: Springer International Publishing
Published in: Drug Safety / Issue 10/2007
Print ISSN: 0114-5916
Electronic ISSN: 1179-1942
DOI: https://doi.org/10.2165/00002018-200730100-00067

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Poster Presentations

Excerpt

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 10/2007